Skip to content

CIK 0001697532

APLT Applied Therapeutics, Inc.

Insider trading from SEC Form 4. Last filing Feb 4, 2026.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company

Signals

Open-market buys and sells at Applied Therapeutics, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
25WeakStacy J. Kanter
director
sell
$4,816
43,000 shares
-40%-
30WeakConstantine Chinoporos
See Remarks
sell
$197
447 shares
-0%-
30WeakLeslie D. Funtleyder
See Remarks
sell
$6,381
14,502 shares
-4%-
30WeakRiccardo Perfetti
Chief Medical Officer
sell
$4,561
10,366 shares
-1%-
30WeakConstantine Chinoporos
See Remarks
sell
$17k
28,117 shares
-9%-
37WeakRiccardo Perfetti
Chief Medical Officer
sell
$53k
86,078 shares
-9%-
30WeakLeslie D. Funtleyder
See Remarks
sell
$14k
22,950 shares
-5%-

Transactions

The last 64 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Feb 3, 2026Stacy J. Kanter
director
DDisposition to issuer
Common Stock
-22,500--42,500Feb 4, 2026
Feb 3, 2026Stacy J. Kanter
director
UTender of shares
Common Stock
-42,500--0Feb 4, 2026
Feb 3, 2026Stacy J. Kanter
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-20,460--0Feb 4, 2026
Feb 3, 2026Stacy J. Kanter
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-10,230--0Feb 4, 2026
Feb 3, 2026Stacy J. Kanter
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-16,500--0Feb 4, 2026
Feb 3, 2026Stacy J. Kanter
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-16,500--0Feb 4, 2026
Feb 3, 2026Stacy J. Kanter
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-200,000--0Feb 4, 2026
Feb 3, 2026Jay S Skyler
director
DDisposition to issuer
Common Stock
-22,500--42,500Feb 3, 2026
Dec 19, 2025Evan Prescott Bailey
Chief Medical Officer
AGrant or award
Common Stock
+437,500$0.00$01,296,816Feb 3, 2026
Dec 19, 2025Leslie D. Funtleyder
Chief Financial Officer
AGrant or award
Common Stock
+1,187,500$0.00$02,527,959Feb 3, 2026
Dec 19, 2025Constantine Chinoporos
See Remarks
AGrant or award
Common Stock
+437,500$0.00$01,057,111Feb 3, 2026
Dec 19, 2025Corwin Dale Hooks
Chief Commercial Officer
AGrant or award
Common Stock
+312,500$0.00$0868,253Feb 3, 2026
Feb 3, 2026Teena Lerner
director
DDisposition to issuer
Common Stock
-22,500--82,922Feb 3, 2026
Feb 3, 2026Corwin Dale Hooks
Chief Commercial Officer
DDisposition to issuer
Common Stock
-862,500--5,753Feb 3, 2026
Feb 3, 2026Constantine Chinoporos
See Remarks
DDisposition to issuer
Common Stock
-1,000,000--57,111Feb 3, 2026
Feb 3, 2026Jay S Skyler
director
UTender of shares
Common Stock
-42,500--0Feb 3, 2026
Feb 3, 2026Teena Lerner
director
UTender of shares
Common Stock
-82,922--0Feb 3, 2026
Feb 3, 2026Leslie D. Funtleyder
Chief Financial Officer
DDisposition to issuer
Common Stock
-2,375,000--152,959Feb 3, 2026
Feb 3, 2026Evan Prescott Bailey
Chief Medical Officer
DDisposition to issuer
Common Stock
-1,235,915--60,901Feb 3, 2026
Feb 3, 2026Teena Lerner
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-20,460--0Feb 3, 2026
Feb 3, 2026Corwin Dale Hooks
Chief Commercial Officer
UTender of shares
Common Stock
-5,753--0Feb 3, 2026
Feb 3, 2026Leslie D. Funtleyder
Chief Financial Officer
UTender of shares
Common Stock
-152,959--0Feb 3, 2026
Feb 3, 2026Jay S Skyler
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-20,460--0Feb 3, 2026
Feb 3, 2026Constantine Chinoporos
See Remarks
UTender of shares
Common Stock
-57,111--0Feb 3, 2026
Feb 3, 2026Evan Prescott Bailey
Chief Medical Officer
UTender of shares
Common Stock
-60,901--0Feb 3, 2026
Feb 3, 2026Evan Prescott Bailey
Chief Medical Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-19,531--0Feb 3, 2026
Feb 3, 2026Leslie D. Funtleyder
Chief Financial Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-20,460--0Feb 3, 2026
Feb 3, 2026Jay S Skyler
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-10,230--0Feb 3, 2026
Feb 3, 2026Teena Lerner
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-10,230--0Feb 3, 2026
Feb 3, 2026Jay S Skyler
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-16,500--0Feb 3, 2026
Feb 3, 2026Leslie D. Funtleyder
Chief Financial Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-10,230--0Feb 3, 2026
Feb 3, 2026Teena Lerner
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-16,500--0Feb 3, 2026
Feb 3, 2026Evan Prescott Bailey
Chief Medical Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-4,883--0Feb 3, 2026
Feb 3, 2026Teena Lerner
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-16,500--0Feb 3, 2026
Feb 3, 2026Jay S Skyler
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-16,500--0Feb 3, 2026
Feb 3, 2026Leslie D. Funtleyder
Chief Financial Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-16,500--0Feb 3, 2026
Feb 3, 2026Jay S Skyler
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-200,000--0Feb 3, 2026
Feb 3, 2026Teena Lerner
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-200,000--0Feb 3, 2026
Feb 3, 2026Leslie D. Funtleyder
Chief Financial Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-16,500--0Feb 3, 2026
Feb 3, 2026Leslie D. Funtleyder
Chief Financial Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-150,000--0Feb 3, 2026
Feb 3, 2026Teena Lerner
director
DDisposition to issuer
Stock Option (Right to Buy)derivative
-23,941--0Feb 3, 2026
Feb 3, 2026Leslie D. Funtleyder
Chief Financial Officer
DDisposition to issuer
Stock Option (Right to Buy)derivative
-40,502--0Feb 3, 2026
Jan 1, 2026Leslie D. Funtleyder
Chief Financial Officer
AGrant or award
Common Stock
+150,000$0.00$01,340,459Jan 2, 2026
Dec 16, 2025Stacy J. Kanter
director
SOpen-market sale
Common Stock
-43,000$0.11$4,81665,000Dec 18, 2025
Oct 1, 2025Leslie D. Funtleyder
Chief Financial Officer
AGrant or award
Common Stock
+150,000$0.00$01,190,459Oct 1, 2025
Jun 9, 2025Leslie D. Funtleyder
Chief Financial Officer
AGrant or award
Common Stock
+150,000$0.00$0787,121Jul 3, 2025
Jul 1, 2025Leslie D. Funtleyder
Chief Financial Officer
AGrant or award
Common Stock
+150,000$0.00$0937,121Jul 3, 2025
Jun 15, 2025Evan Prescott Bailey
Chief Medical Officer
AGrant or award
Common Stock
+300,000$0.00$0841,669Jun 17, 2025
Jun 9, 2025Jay S Skyler
director
AGrant or award
Stock Option (Right to Buy)derivative
+200,000$0.00$0200,000Jun 11, 2025
Jun 9, 2025Stacy J. Kanter
director
AGrant or award
Stock Option (Right to Buy)derivative
+200,000$0.00$0200,000Jun 11, 2025
Jun 9, 2025Teena Lerner
director
AGrant or award
Stock Option (Right to Buy)derivative
+200,000$0.00$0200,000Jun 11, 2025
Mar 24, 2025Leslie D. Funtleyder
See Remarks
AGrant or award
Common Stock
+350,000$0.00$0740,459Mar 26, 2025
Mar 24, 2025Corwin Dale Hooks
Chief Commercial Officer
AGrant or award
Common Stock
+250,000$0.00$0550,000Mar 26, 2025
Mar 24, 2025Constantine Chinoporos
See Remarks
AGrant or award
Common Stock
+350,000$0.00$0621,436Mar 26, 2025
Mar 4, 2025Constantine Chinoporos
See Remarks
SOpen-market sale
Common Stock
-447$0.44$197271,436Mar 6, 2025
Mar 4, 2025Leslie D. Funtleyder
See Remarks
SOpen-market sale
Common Stock
-14,502$0.44$6,381390,459Mar 6, 2025
Mar 4, 2025Riccardo Perfetti
Chief Medical Officer
SOpen-market sale
Common Stock
-10,366$0.44$4,561890,409Mar 6, 2025
Feb 6, 2025Constantine Chinoporos
See Remarks
SOpen-market sale
Common Stock
-28,117$0.61$17k271,883Feb 7, 2025
Feb 6, 2025Riccardo Perfetti
Chief Medical Officer
SOpen-market sale
Common Stock
-86,078$0.61$53k900,775Feb 7, 2025
Feb 6, 2025Leslie D. Funtleyder
See Remarks
SOpen-market sale
Common Stock
-22,950$0.61$14k404,961Feb 7, 2025
Dec 19, 2024Leslie D. Funtleyder
See Remarks
AGrant or award
Common Stock
+150,000$0.00$0427,911Dec 20, 2024
Dec 19, 2024John Johnson
Executive Chairman
AGrant or award
Common Stock
+500,000$0.00$0500,000Dec 20, 2024
Dec 19, 2024Leslie D. Funtleyder
See Remarks
AGrant or award
Stock Option (Right to Buy)derivative
+150,000$0.00$0150,000Dec 20, 2024
Dec 19, 2024John Johnson
Executive Chairman
AGrant or award
Stock Option (Right to Buy)derivative
+1,000,000$0.00$01,000,000Dec 20, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

APLT insider trading: Applied Therapeutics, Inc. | InsiderTell